NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000
Reuters
Sep 30
NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000
NanoViricides Inc. reported its financial results for the fiscal year ended June 30, 2025. The biopharmaceutical company reported no revenues for both the current and prior fiscal years. Net losses continued as the company has not commenced revenue-generating operations. Research and development expenses increased to $5.549 million for the year ended June 30, 2025, compared to $5.437 million for the year ended June 30, 2024. The increase of $0.112 million was mainly attributed to higher outside laboratory fees related to the preparation of Phase II clinical trial applications. NanoViricides stated its ongoing focus is on advancing drug candidates through preclinical studies and preparing for future clinical trials, with the goal of developing antiviral therapies using nanomedicine approaches. The company noted the potential for future developments in the antiviral field to impact its business plan and market opportunities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-094527), on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.